Objectives : The purpose of this study is to report the clinical effect of herbal medicine on the patient considering chronic renal failure. The patient complained of hemiparesis, general weakness, anorexia, nausea and dizziness. Methods : According to the traditional Korean medicine syndrome differentiation, the patient was classified as Deficiency of Spleen Qi and prescribed Bojungikki-tang and Bojungikki-tang gamibang as well as acupuncture and moxibustion treatment. Changes of BUN, creatinine, VAS for genaral weakness, nausea, dizziness were compared before and after treatment for 2 weeks.Results : After treatment, the level of BUN and creatinine was decreased and main symptoms were improved. Conclusions : Herbal medicine Bojungikki-tang and Bojungikki-tang gamibang with acupuncture and moxibustion treatment would be efficient to the patient of chronic renal failure.
Background
Mild cognitive impairment (MCI) is an intermediate phase between normal aging and dementia. Since a majority of amnestic MCI (aMCI) cases progress to Alzheimer’s disease (AD), it is considered the prodromal stage of AD and, therefore, a treatment target for the prevention of further cognitive decline. However, there is no approved treatment for MCI at present.
Kami Guibi-tang
(KGT) is a herbal drug used in Korean medicine to treat amnesia, insomnia, loss of appetite, and depression. We will explore the effectiveness and safety of KGT in amnestic MCI in this trial.
Methods/design
The study will be a single-center, randomized, placebo-controlled, double-blind trial. Eligible participants diagnosed with amnestic MCI will be randomly allocated to a treatment or control group. Participants will take KGT or placebo granules, three times a day, for 24 weeks. The primary outcomes will be changes in Seoul Neuropsychological Screening Battery (SNSB) scores, and magnetic resonance imaging (MRI) measurements including those of brain metabolites, neurotransmitters, and cerebral blood flow. The secondary outcomes will include the safety assessment, measured by changes in blood chemistry, changes in blood protein and cholesterol levels related to AD pathology, and a comparison of MRI changes between the two groups, using age and genotype as covariates.
Discussion
This study will be the first clinical trial to identify the therapeutic potential of
Kami Guibi-tang
for amnestic MCI. The findings will provide insight into the feasibility of large-scale trials to gather evidence for KGT as a treatment for MCI.
Trial registration
Korean Clinical Trial Registry, ID:
KCT0002407
. Registered on 30 March 2017.
Electronic supplementary material
The online version of this article (10.1186/s13063-019-3567-1) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.